Dr. Isaac Bright joined Imagion Biosystems as Chief Executive Officer in June 2023. Before entering Imagion, Dr. Bright served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics, Inc. before its trade sale to iBio, Inc. (NYSEA: IBIO) in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell, Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics, Inc. and consulting Chief Business Officer for synthetic biology innovator musebio, Inc. (currently Incripta, Inc.) as it secured its $23M Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150M Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab, Inc., Kalila Medical, Inc. until its acquisition by Abbott (NYSE: ABT), and Twist Bioscience before its IPO (NASDAQ: TWST). Dr. Bright’s startup experience began as he built and led QuantaLife, Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories, Inc. (NYSE: BIO). Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development – Neuromodulation for global medtech leader Medtronic (NYSE: MDT). Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania.
Highlighting our dedicated employees who bring both their experience and passions to Imagion Biosystems: What experience do you bring prior to joining IB? I